Rapidus Ushers in New Era with Operational 2nm Chip Prototype
On July 18, Rapidus, the company spearheading Japan's efforts to domestically produce next-generation semiconductors, hosted a customer event at a hotel in Chitose, Hokkaido.
The venue was located near the site of the company's semiconductor manufacturing facility, which is currently under construction.
Speaking at a press conference beforehand, President and CEO Atsuyoshi Koike announced that the pilot production line, launched in April 2025, was running smoothly. He also revealed that the company had successfully confirmed the operation of a prototype 2-nanometer semiconductor chip. This marks a major milestone in Japan's semiconductor ambitions.
Chairman Tetsuro Higashi of Rapidus, Hokkaido Governor Naomichi Suzuki, and Chitose Mayor Ryuichi Yokota also attended the press conference.
President Koike underscored the significance of the achievement, calling the 2-nanometer prototype Japan's first and a groundbreaking milestone. "We achieved this at an unprecedented speed," he said. Looking ahead, he stated that Rapidus will continue refining the chip with the goal of entering mass production by 2027. Attendees at the press conference (from left) Rapidus Chairman Tetsuro Higashi, President and CEO Atsuyoshi Koike, Hokkaido Governor Naomichi Suzuki, and Chitose Mayor Ryuichi Yokota. July 18, Chitose City, Hokkaido (©Sankei by Takahiro Sakamoto)
Governor Suzuki expressed strong optimism, stating, "Today marks a major milestone in the history of Hokkaido's semiconductor industry." He also affirmed his commitment to ongoing support.
On the same day, members of the media were given a tour of the new IIM-1 factory, which is now approximately 80% complete. The customer event at the hotel drew around 200 participants, including suppliers and prospective business partners from around the world.
Author: Takahiro Sakamoto, The Sankei Shimbun
このページを 日本語 で読む
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
2 days ago
- Toronto Sun
Caitlin Clark's WNBA rookie card fetches record $660,000
Nearly twice price of earlier sale of Clark card. Published Jul 25, 2025 • 1 minute read Indiana Fever's Caitlin Clark reacts on the sideline during the first half of a WNBA basketball game against the Las Vegas Aces, Thursday, July 24, 2025, in Indianapolis. Photo by Darron Cummings / AP Caitlin Clark has set yet another record, this time with her 2024 WNBA rookie card selling for the most money yet for a female athlete at a public auction. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Clark's Rookie Royalty WNBA Flawless Logowoman 1/1 card sold Thursday night for $660,000. That sale price tops the previous mark of $366,000 for Clark's 2024 Panini Prizm WNBA Signatures Gold Vinyl 1/1 PSA 10 in March. The card that sold Thursday night is signed and inscribed with Clark's scoring total for her rookie season. The card also includes a Logowoman patch seen on WNBA jerseys, making such cards a top pick for collectors. This card entered extended bidding at $336,000 before reaching the final sale price. The Flawless Logowoman was one of seven Clark cards sold at Fanatics Collect on Thursday night and one of four cards from Panini America's 2024 Rookie Royalty WNBA collection. Now 14 cards featuring Clark have sold at public auction easily topping her salary this season with the Indiana Fever, with the latest going for more than Clark is scheduled to make over her rookie contract with Indiana. This mark may be challenged Aug. 9 when an Immaculate Logowoman 1/1 Clark card is scheduled for sale. The price for that card was at $180,000 on Thursday night before a buyer's premium on 17 bids. Toronto & GTA Sports Toronto & GTA Hockey News
Toronto Star
2 days ago
- Toronto Star
Caitlin Clark's WNBA rookie card fetches $660,000 at auction in a record-breaking sale
Caitlin Clark has set yet another record, this time with her 2024 WNBA rookie card selling for the most money yet for a female athlete at a public auction. Clark's Rookie Royalty WNBA Flawless Logowoman 1/1 card sold Thursday night for $660,000. That sale price tops the previous mark of $366,000 for Clark's 2024 Panini Prizm WNBA Signatures Gold Vinyl 1/1 PSA 10 in March.
Cision Canada
4 days ago
- Cision Canada
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
HERZLIYA, Israel and CALGARY, Alberta, July 23, 2025 /CNW/ -- Innocan Pharma Corporation (" Innocan" or the " Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the " SEC") relating to a proposed public offering of units (each, a " Unit" and collectively, the " Units") in the United States. Each Unit will be comprised of one common share of the Company (a " Common Share") and one common share purchase warrant of the Company (a " Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price and term in the context of the market. Innocan has applied to list its Common Shares and Warrants on the Nasdaq Capital Market under the symbols "INNP" and "INNPW", respectively. ThinkEquity is acting as sole book-running manager for the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity, 17 State Street, 41 st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website located at A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Iris Bincovich Innocan Pharma's CEO stated: "The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels." About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales, through its BI Sky Global Ltd. subsidiary. For further information, please contact: Iris Bincovich, CEO 15162104025+ +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Disclaimer for Forward-Looking Information This press release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws and/or "forward-looking statements" within the meaning of applicable United States securities laws (collectively, "forward-looking statements"). Forward-looking statements relate to future events or future performance and reflect the Company's current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to: statements relating to the public offering of the Company's common shares; the expected timing of the public offering; the registration and listing of the Company's common shares in the United States; the registration statement becoming effective; the SEC's review process; the sizing and pricing of the offering; the means by which the offering will be made; and the Company's business strategies. Often, but not always, forward-looking statements may be identified by the use of words such as "expects", "anticipates", "plans", "projects", "estimates", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements in this press release are based upon, without limitation, the following estimates and assumptions: the Company carrying out its public offering; the Company successfully completing the SEC review process; obtaining requisite regulatory approvals; and general business, economic and market conditions. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Important factors that may cause actual results to vary, include, without limitation, that the Company may not carry out its public offering or complete the SEC review process. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Readers are cautioned that reliance on such information may not be appropriate for other purposes.
